Retatrutide is being called a “triple G” obesity drug because it targets three different gut hormones involved in appetite, metabolism, and blood sugar regulation: GLP-1, GIP, and glucagon. Current drugs like Wegovy mainly target GLP-1, while Zepbound targets GLP-1 and GIP. Researchers believe Retatrutide’s three-pronged approach may explain its stronger effects on appetite suppression and calorie burning.
